PeptideDB

ATP dipotassium (adenosine 5'-triphosphate dipotassium) 42373-41-1

ATP dipotassium (adenosine 5'-triphosphate dipotassium) 42373-41-1

CAS No.: 42373-41-1

ATP dipotassium (Adenosine 5'-triphosphate dipotassium) is an important substance for energy storage and metabolism in t
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

ATP dipotassium (Adenosine 5'-triphosphate dipotassium) is an important substance for energy storage and metabolism in the body, providing energy for metabolism and functioning as a coenzyme in cells. ATP dipotassium is an important endogenous signaling molecule in immunity and inflammation.

Physicochemical Properties


Molecular Formula C10H16K2N5O13P3
Molecular Weight 585.38
Exact Mass 582.908
CAS # 42373-41-1
Related CAS # ATP;56-65-5;ATP disodium trihydrate;51963-61-2;ATP ditromethamine;102047-34-7;ATP-13C dilithium;ATP-15N5,d14 dilithium;ATP-d14 dilithium;ATP-15N5 dilithium;ATP-13C10 dilithium
PubChem CID 87469918
Appearance Typically exists as solid at room temperature
Hydrogen Bond Donor Count 5
Hydrogen Bond Acceptor Count 17
Rotatable Bond Count 8
Heavy Atom Count 33
Complexity 789
Defined Atom Stereocenter Count 4
SMILES

C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)OP(=O)(O)[O-])O)O)N.[K+].[K+]

InChi Key MRTZQELCVZCIFU-UHFFFAOYSA-N
InChi Code

InChI=1S/C10H16N5O13P3.2K/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20;;/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20);
Chemical Name

C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N.[K].[K]
Synonyms

Adenosine 5'-triphosphate dipotassium
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets Human Endogenous Metabolite
ln Vitro The activation of the NLRP3 inflammasome in HGFs is synergistically affected by co-treatment with ATP dipotassium (5 mM; 1 hour) and LPS (1 μg/mL)[3]. BMDMs secrete IL-1β, KC, and MIP-2 in response to ATP dipotassium (2 mM; 0.5-24 hours) in a way that is dependent on caspase-1 activation[4]. In vitro neutrophil chemotaxis is facilitated by ATP dipotassium[4].
ln Vivo In vivo protection from bacterial infection in mice is provided by ATP dipotassium (50 mg/kg; ip)[4]. In vivo, ATP dipotassium triggers the release of IL-1β, KC, and MIP-2 as well as the recruitment of neutrophils[4].
Animal Protocol Animal/Disease Models: Four- week-old Kunming mice (18-22 g)[4]
Doses: 50 mg/kg
Route of Administration: intraperitoneal (ip)injection, before bacterial (E. coli) challenge
Experimental Results: Protected mice from bacterial infection.
References

[1]. ATP synthesis and storage. Purinergic Signal. 2012 Sep;8(3):343-57.

[2]. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006 Nov;112(2):358-404.

[3]. Doxycycline inhibits NAcht Leucine-rich repeat Protein 3 inflammasome activation and interleukin-1β production induced by Porphyromonas gingivalis-lipopolysaccharide and adenosine triphosphate in human gingival fibroblasts. Arch Oral Biol. 2019 Nov;107:104514.

[4]. Adenosine-5'-Triphosphate (ATP) Protects Mice against Bacterial Infection by Activation of the NLRP3 Inflammasome. PLoS One. 2013; 8(5): e63759.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.7083 mL 8.5415 mL 17.0829 mL
5 mM 0.3417 mL 1.7083 mL 3.4166 mL
10 mM 0.1708 mL 0.8541 mL 1.7083 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.